In proof-of-concept studies, NNMT inhibitors (NNMTis) have demonstrated promise as potential treatments for obesity and obesity-related metabolic comorbidities (e.g., T2D, fatty liver)8,9,13. The gene discussed is NNMT; the disease is obesity due to melanocortin 4 receptor deficiency.